These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy. Goodkin DE; Plencner S; Palmer-Saxerud J; Teetzen M; Hertsgaard D Arch Neurol; 1987 Aug; 44(8):823-7. PubMed ID: 2820359 [TBL] [Abstract][Full Text] [Related]
4. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH]. Wender M; Tokarz-Kupczyk E; Mularek O Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886 [TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide]. Wajgt A; Szyrocka-Szwed K; Gadomska B; Szczechowski L Neurol Neurochir Pol; 1988; 22(6):518-23. PubMed ID: 3077433 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide in multiple sclerosis. Millac P; Miller H Lancet; 1969 Apr; 1(7598):783. PubMed ID: 4180869 [No Abstract] [Full Text] [Related]
7. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517 [TBL] [Abstract][Full Text] [Related]
8. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside. Cendrowski W Acta Neurol Belg; 1973; 73(4):209-19. PubMed ID: 4770124 [No Abstract] [Full Text] [Related]
9. Cyclophosphamide therapy for MS. Gauthier SA; Weiner HL Int MS J; 2005 Aug; 12(2):52-8. PubMed ID: 16417815 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of multiple sclerosis with intravenous hydrocortisone hemisuccinate in combination with cyclophosphamide or cytosine arabinoside]. Cendrowski W Neurol Neurochir Pol; 1974; 8(1):47-52. PubMed ID: 4407711 [No Abstract] [Full Text] [Related]
12. Conditioning of cyclophosphamide-induced leukopenia in humans. Giang DW; Goodman AD; Schiffer RB; Mattson DH; Petrie M; Cohen N; Ader R J Neuropsychiatry Clin Neurosci; 1996; 8(2):194-201. PubMed ID: 9081556 [TBL] [Abstract][Full Text] [Related]
13. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. Gobbini MI; Smith ME; Richert ND; Frank JA; McFarland HF J Neuroimmunol; 1999 Sep; 99(1):142-9. PubMed ID: 10496187 [TBL] [Abstract][Full Text] [Related]
14. The use of cyclophosphamide in the treatment of multiple sclerosis. Weiner HL; Hauser SL; Hafler DA; Fallis RJ; Lehrich JR; Dawson DM Ann N Y Acad Sci; 1984; 436():373-81. PubMed ID: 6099707 [No Abstract] [Full Text] [Related]
18. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Weiner HL; Cohen JA Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872 [TBL] [Abstract][Full Text] [Related]